Hosted by https://biobizbuzz.com/ · 🇺🇸 US · EN-GB · 28 episodes
Established thought leaders with verified media credentials.
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. Disclaimer https://biobizbuzz.com/disclaimer/
https://biobizbuzz.com/ hosts BioBiz Buzz, a news show with 28 episodes published.
In this episode of BioBiz Buzz, your host Mike Ward explores a critical, but often underappreciated, driver of vision loss in retinal diseases; the breakdown of the blood–retina barrier (BRB). While anti-VEGF therapies h
In this episode of BioBiz Buzz, Mike Ward talks to Dr Sam Possemiers, founder and CEO of Belgium-based MRM Health, about what it really takes to turn the human gut microbiome into a bona fide drug modality. They trace th
Targeted protein degradation has moved from elegant academic concept to one of the most closely watched frontiers in oncology, promising to drug the 80% of disease‑driving proteins that traditional inhibitors and even AD
For years, the narrative was simple: if you wanted a multibillion-dollar biotech outcome, you built in Boston or the Bay Area. Gilead’s up to $5 billion acquisition of Munich-based Tubulis just blew that up. In this epis
Progress in developing safe and effective therapies for amyotrophic lateral sclerosis (ALS) has been painfully slow. It is caused by the death of motor neurons in the central nervous system and the spinal cord, which lea
What if an annual self-injection could silence your hidden cardiac risk instead of just lowering your LDL? In this episode of BioBiz Buzz, Mike Ward sits down with David Solomon, CEO of Thalia Therapeutics, to unpack how
For more than three decades, transcription factors have been the great white whale of oncology drug discovery; tantalising, genetically validated, mechanistically central, and yet stubbornly out of reach. They sit at the
Multiple myeloma remains the second-largest blood cancer globally with no cure, and despite recent breakthroughs in CAR-T and antibody therapies, patients continue to relapse, often losing the very antigens that therapie
In this episode of BioBiz Buzz, your host Mike Ward sits down with Dr. Jared Baeten, Senior Vice President for Clinical Development and Head of the Virology Therapeutic Area at Gilead Sciences, to explore how new data fr
2025 has been a seismic year for the pharmaceutical industry, a year of extremes where innovation superpowers emerge alongside spectacular collapses. In this special episode, BioBiz Buzz host Jo Shorthouse sits down with
Engineered T-cell receptor (TCR) therapies promise to do for solid tumours what chimeric antigen receptor T-cell (CAR-T) therapies have done for haematological malignancies. The two approaches are conceptually similar –
The traditional biotech funding model hasn't fundamentally changed in decades: brilliant founders with promising science face an impossible choice; build expensive internal R&D capabilities or negotiate partnerships on t
In a fundraising environment marked by cautious institutional investors, tightening belts, and widespread scepticism about early-stage venture capital, Sofinnova Partners has just closed its flagship Capital XI fund at €
This episode of BioBiz Buzz explores AL-S Pharma's pioneering approach to treating amyotrophic lateral sclerosis through AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1 protein. Host Mike Ward speak
GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge. US-based Vivani Me
Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025 to as much as USD 9.85 billion by 2035. Thi
Breast cancer affects women of all ages after puberty in every country. In 2022, the disease struck an estimated 2.3 million women and claimed 670 000 lives globally, according to the World Health Organization. The Globa
AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates of incidence and mortality, software solu
In a disease where hope has been scarce for decades, Belgian biotech Bioxodes is rewriting the rules of stroke treatment. Join your host Mike Ward in conversation with CEO Marc Dechamps as he reveals how his team transfo
The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit patient access to the
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
BioBiz Buzz has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their news audience.
BioBiz Buzz is hosted by https://biobizbuzz.com/. The show is categorised under news (commentary) and has published 28 episodes.
BioBiz Buzz has published 28 episodes.
BioBiz Buzz regularly covers news, commentary, business. It sits in the news category, with a commentary focus.
BioBiz Buzz is accessible for guests with genuine news expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
BioBiz Buzz hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of BioBiz Buzz average 27 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates BioBiz Buzz's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 8 days ago.
